TCA
NVS icon

Transcend Capital Advisors’s Novartis NVS Stock Holding History

Transcend Capital Advisors’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Sell
8,348
-745
-8% -$112K 0.09% 214
2026
Q1 		$1.39M Sell
9,093
-134
-1% -$20.5K 0.11% 178
2025
Q4 		$1.27M Sell
9,227
-436
-5% -$57.1K 0.1% 194
2025
Q3 		$1.24M Sell
9,663
-490
-5% -$59.8K 0.09% 215
2025
Q2 		$1.23M Sell
10,153
-249
-2% -$28.1K 0.09% 192
2025
Q1 		$1.16M Buy
10,402
+14
+0.1% +$1.49K 0.08% 231
2024
Q4 		$1.01M Sell
10,388
-45
-0.4% -$4.8K 0.07% 237
2024
Q3 		$1.2M Sell
10,433
-740
-7% -$84K 0.08% 237
2024
Q2 		$1.19M Sell
11,173
-47
-0.4% -$4.72K 0.09% 227
2024
Q1 		$1.09M Sell
11,220
-100
-0.9% -$10.3K 0.09% 220
2023
Q4 		$1.14M Sell
11,320
-192
-2% -$18.5K 0.1% 202
2023
Q3 		$1.17M Sell
11,512
-573
-5% -$58.2K 0.11% 184
2023
Q2 		$1.22M Buy
12,085
+169
+1% +$16.9K 0.12% 186
2023
Q1 		$1.1M Sell
11,916
-466
-4% -$40.7K 0.11% 186
2022
Q4 		$1.12M Sell
12,382
-237
-2% -$20K 0.12% 188
2022
Q3 		$959K Sell
12,619
-146
-1% -$12.1K 0.11% 196
2022
Q2 		$1.08M Sell
12,765
-942
-7% -$82.6K 0.11% 191
2022
Q1 		$1.2M Buy
13,707
+409
+3% +$35.4K 0.11% 196
2021
Q4 		$1.16M Buy
13,298
+1,426
+12% +$118K 0.1% 198
2021
Q3 		$1.01M Buy
+11,872
New +$1.07M 0.09% 212
2021
Q2 		– Sell
-12,003
Closed -$1.02M – 392
2021
Q1 		$1.02M Sell
12,003
-394
-3% -$35.4K 0.12% 177
2020
Q4 		$1.17M Buy
12,397
+592
+5% +$51.7K 0.15% 150
2020
Q3 		$1.03M Buy
11,805
+439
+4% +$38K 0.19% 112
2020
Q2 		$993K Sell
11,366
-2,789
-20% -$241K 0.32% 77
2020
Q1 		$1.17M Sell
14,155
-518
-4% -$46.2K 0.35% 81
2019
Q4 		$1.39M Buy
+14,673
New +$1.32M 0.37% 85

Other funds holding NVS

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Transcend Capital Advisors's NVS Position: Q2 2026 in Review

Transcend Capital Advisors reduced its Novartis (NVS) stake by 8.2% in Q2 2026, selling an estimated $112K and leaving 8,348 shares worth $1.31M. The position accounts for 0.09% of the portfolio, ranked #214.

Transcend Capital Advisors first reported a position in NVS in Q4 2019 and has held it in 26 quarters since. The position peaked at $1.39M in Q4 2019. 1,625 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Transcend Capital Advisors held 8,348 shares of Novartis worth $1.31M as of Q2 2026.
  • Transcend Capital Advisors sold 745 Novartis shares in Q2 2026, an estimated $112K.
  • Novartis made up 0.09% of Transcend Capital Advisors's portfolio in Q2 2026, its #214 holding.
  • Transcend Capital Advisors first reported a position in Novartis in Q4 2019 and has held it in 26 quarters since.
  • Transcend Capital Advisors's Novartis position peaked at $1.39M in Q4 2019.
  • 1,625 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.